CD4 and neoplasm: Further transcriptional profiling of DP CD4+ TILs may uncover additional biomarkers and pathway factors that may be therapeutically targeted to selectively reinforce or improve tumor antigen–specific DP Th cell bioactivity within the TME to benefit patient outcomes.